Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Kansas Medical Center Identifier:
First received: June 2, 2000
Last updated: January 12, 2017
Last verified: January 2017

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen.

PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the biomarkers of the tumor tissue, compared with LY353381, in treating women with newly diagnosed breast cancer.

Condition Intervention Phase
Breast Cancer
Drug: arzoxifene hydrochloride
Drug: tamoxifen citrate
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer

Resource links provided by NLM:

Further study details as provided by University of Kansas Medical Center:

Study Start Date: July 2000
Study Completion Date: August 2002
Primary Completion Date: August 2002 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine whether LY353381 hydrochloride or tamoxifen administered in the interval between biopsy and re-excision alters the expression of tissue biomarkers relative to placebo controls in postmenopausal women with newly diagnosed breast cancer.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.

  • Phase I: Patients are randomized to receive either oral LY353381 hydrochloride or oral placebo daily.

Upon completion of phase I, all treatment centers begin phase II of the study.

  • Phase II: Patients are randomized to receive either oral tamoxifen or oral placebo daily.

Treatment in both phases continues for 2-6 weeks (until scheduled lumpectomy or mastectomy) in the absence of disease progression or unacceptable toxicity.

Patients are followed at 1 and 2 weeks after surgery.

PROJECTED ACCRUAL: A minimum of 120 patients (60 per treatment phase) will be accrued for this study within 18 months.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed noninvasive or small invasive breast cancer

    • Low or intermediate grade (ductal carcinoma in situ, T1, or T2) OR
    • Estrogen and/or progesterone receptor positive
    • Largest mass no greater than 5 cm
    • Clustered microcalcifications as only abnormality allowed with no upper size limit
    • If no distinction between mass and microcalcifications, size as 1 lesion
  • Lumpectomy or mastectomy must be planned for 2-6 weeks from start of study
  • No evidence of metastases from any malignancy
  • Hormone receptor status:

    • Estrogen and progesterone receptor positive (unless low or intermediate grade tumor)



  • 18 and over


  • Female

Menopausal status:

  • Postmenopausal by one of the following:

    • Prior oophorectomy
    • Over age 50 with prior hysterectomy, ovaries remaining
    • Uterus and ovaries intact and no menstrual period for more than 3 months

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Platelet count greater than 100,000/mm^3
  • Hemoglobin greater than 10 g/dL
  • Absolute granulocyte count greater than 1,000/mm^3


  • Albumin greater than 3 g/dL
  • Bilirubin less than 1.5 mg/dL
  • AST less than 100 U/L
  • Alkaline phosphatase less than 200 U/L


  • Creatinine less than 1.5 mg/dL


  • No history of deep vein thrombosis


  • No prior pulmonary embolus


  • Not pregnant or nursing


Biologic therapy:

  • Not specified


  • At least 1 year since prior chemotherapy

Endocrine therapy:

  • At least 1 year since prior aromatase inhibitors, antiestrogens, or LH agonists/antagonists
  • No concurrent hormone replacement therapy or oral contraceptives (from time of randomization)


  • Not specified


  • See Disease Characteristics


  • No concurrent treatment for other malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005886

United States, Alabama
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294-3300
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Comprehensive Cancer Centers of the Desert
Palm Springs, California, United States, 92262
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160-7357
United States, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States, 43210-1240
United States, Pennsylvania
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, United States, 19107-5541
United States, Texas
U.S. Oncology Research Inc.
Dallas, Texas, United States, 75246
Sponsors and Collaborators
University of Kansas Medical Center
National Cancer Institute (NCI)
Study Chair: Carol J. Fabian, MD University of Kansas
  More Information

Responsible Party: University of Kansas Medical Center Identifier: NCT00005886     History of Changes
Other Study ID Numbers: CDR0000067956
Study First Received: June 2, 2000
Last Updated: January 12, 2017

Keywords provided by University of Kansas Medical Center:
stage I breast cancer
stage II breast cancer
ductal breast carcinoma in situ
breast cancer in situ

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents processed this record on April 26, 2017